ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dexamethasone phosphate

Also written as “Moxidex otic solution”, “Dexamethasone sodium phosphate” and “Dexamethasone Phosphate Ophthalmic Solution”.

Its studies are mostly in Otitis Media · Ataxia Telangiectasia · Peripheral Arterial Disease · Uveitis, Anterior · Cataract, led by 5 companies.

Drug pageDexamethasone phosphate: every studyMany companies study it; this page follows only the 20 they lead. All 66 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 20, 201020 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eyegate Pharmaceuticalsits history only70 open or runningphase 3since May 20, 2010Jun 5, 2008none ahead
Alconits history only60 open or runningphase 3since Dec 19, 2007Dec 19, 2007none ahead
Quince Therapeuticsits history only30 open or runningphase 3since Dec 11, 2023Jul 28, 2010none ahead
Mercator MedSystems20 open or runningphase 4since Nov 4, 2013Nov 4, 2013none ahead
Taiwan Liposomeits history only20 open or runningphase 2since Nov 13, 2013Nov 13, 2013none ahead

Also a collaborator on its studies: Biotrial.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Mercator MedSystems only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2013First study: phase 4 study in Peripheral Arterial DiseaseFirst studyNCT01983449 · 285 enrolled · United States
  2. May 6, 2019Phase 2 study in Peripheral Arterial DiseaseNCT03942601 · 10 enrolled · United States

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

All 2 Mercator MedSystems leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03942601Peripheral Arterial Disease · United States2TerminatedApr 30, 202110
NCT01983449Peripheral Arterial Disease · United States4CompletedDec 2016285

How it is read

Names in the registry

  • “Moxidex otic solution”, 5 entries
  • “Dexamethasone sodium phosphate”, 2 entries
  • “Dexamethasone Phosphate Ophthalmic Solution”, 2 entries
  • “Low-dose TGF-B3 and Dexamethasone Sodium Phosphate”, 1 entry
  • “High-dose TGF-B3 and Dexamethasone Sodium Phosphate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.